What is chromium and what does it do?
Chromium is an essential trace mineral required in very small amounts for normal metabolic function. Its primary biological role is in insulin signalling — chromium potentiates the action of insulin at the receptor level, helping the hormone do its job more efficiently.
This mechanism underpins the EU-authorised health claim that chromium "contributes to the maintenance of normal blood glucose levels." It is not that chromium lowers blood sugar directly. Rather, it supports the normal process by which insulin facilitates glucose uptake from the bloodstream into cells.
Chromium is also involved in the metabolism of carbohydrates, fats and proteins. The authorised claim that it "contributes to normal macronutrient metabolism" reflects this broader metabolic role. A review by Cefalu & Hu (2004) examined the molecular mechanisms through which chromium supports insulin action and metabolic function, confirming its role as an essential cofactor in these pathways.
What are the authorised EU health claims for chromium?
Under EU Regulation 432/2012 (retained in UK law post-Brexit), chromium carries three authorised health claims. These are the only claims that can legally be made about chromium in food supplements:
- "Contributes to the maintenance of normal blood glucose levels"
- "Contributes to normal macronutrient metabolism"
- "Contributes to normal energy-yielding metabolism"
Each claim has been assessed by the European Food Safety Authority (EFSA) and deemed to have sufficient scientific evidence behind it. They use precise, measured language for a reason — "contributes to" and "maintenance of normal" mean that chromium supports existing healthy function. They do not mean it treats, corrects or reverses any disease state.
These are not marketing phrases. They are regulatory determinations based on systematic evidence review, and they set the boundary for what can and cannot be said about chromium supplementation.
Why chromium picolinate specifically?
Chromium exists in several supplemental forms, including chromium chloride, chromium nicotinate and chromium picolinate. Of these, chromium picolinate — a chelate of trivalent chromium with picolinic acid — is the most extensively studied.
The bioavailability advantage of the picolinate form has been demonstrated directly. DiSilvestro & Dy (2007) compared the acute absorption of four commercially available chromium supplements in young adult females, measuring 24-hour urinary chromium excretion as an indirect marker of absorption. Chromium picolinate produced significantly higher urinary chromium levels than either of two nicotinate supplements or chromium chloride, indicating superior intestinal absorption.
Laschinsky et al. (2012) confirmed this in a study examining bioavailability in both rats and humans. True absorption of chromium from chromium picolinate was approximately twice that of chromium chloride. The picolinic acid chelate appears to facilitate transport across the intestinal wall more effectively than inorganic chromium salts.
This is why chromium picolinate is the form used in the majority of clinical trials — and why PARTICULAR selected it for its formulations.
What does the clinical evidence say about blood glucose?
The landmark study in this area was conducted by Anderson et al. (1997), who randomised 180 men and women with type 2 diabetes into three groups: placebo, 200 µg/day chromium picolinate, or 1000 µg/day chromium picolinate. After four months, the higher-dose group showed significant improvements in HbA1c (a marker of long-term blood glucose control), fasting glucose and insulin levels compared to placebo. The lower-dose group showed improvements in some but not all measures.
This was a well-designed trial, but it is important to note the population: these were individuals with established type 2 diabetes. The results cannot be directly generalised to healthy individuals with normal glucose metabolism.
A systematic review by Balk et al. (2007) assessed the broader evidence across multiple randomised controlled trials. Their conclusion was nuanced: chromium supplementation significantly improved glycaemia among patients with diabetes, but no significant effect was found in people without diabetes. The authors noted that the quality of evidence was limited by small sample sizes and methodological variability across studies.
This is an honest summary of where the science stands. The EU-authorised claim — that chromium "contributes to the maintenance of normal blood glucose levels" — is supported by the totality of evidence, including the mechanistic role of chromium in insulin signalling. But it is not a treatment for diabetes, and anyone with concerns about blood sugar should consult their GP.
Does chromium help with weight loss?
This question comes up frequently, and it deserves a straightforward answer.
Pittler et al. (2003) conducted a meta-analysis of ten randomised trials examining chromium picolinate and body weight. They found a statistically significant but very small effect: a weighted mean difference of -1.1 kg in favour of chromium picolinate. However, when sensitivity analysis removed a single outlier trial, the effect was no longer statistically significant (-0.9 kg, 95% CI -2.0 to 0.2 kg).
The authors concluded that the clinical relevance of such a small effect is debatable, and the lack of robustness means the result should be interpreted with caution.
To be clear: chromium is not a weight loss supplement. The authorised claim is that it "contributes to normal macronutrient metabolism" — this means it plays a role in how your body processes carbohydrates, fats and proteins under normal conditions. It does not mean it accelerates fat loss, suppresses appetite or changes body composition in a meaningful way.
If you encounter products marketing chromium as a weight loss ingredient, that should raise questions about the rigour of their other claims.
How common is chromium deficiency?
True clinical chromium deficiency is rare. It has been documented primarily in patients receiving long-term parenteral nutrition without chromium supplementation — a very specific clinical scenario.
However, suboptimal chromium intake is a different matter. Chromium is found in foods such as broccoli, wholegrains, meat and brewer's yeast, but the amounts are small and highly variable depending on soil conditions and food processing. Diets high in refined carbohydrates are particularly relevant because refined sugar and white flour contain very little chromium, and high sugar intake increases urinary chromium excretion — creating a situation where demand rises while supply falls.
The UK does not set a Reference Nutrient Intake (RNI) for chromium, reflecting the difficulty of establishing precise requirements. The EU adequate intake is 40 µg/day. EFSA has acknowledged the evidence for chromium's role in glucose metabolism while noting that optimal intake levels remain an area of ongoing research.
Who might benefit from chromium supplementation?
Based on the authorised claims and clinical evidence, chromium supplementation may be relevant for:
- People with high refined carbohydrate intake — whose diets may be low in chromium while simultaneously increasing chromium excretion
- People with blood sugar concerns — though this should always be discussed with a GP, particularly for anyone with diagnosed diabetes or taking medication that affects blood glucose
- People whose health goals include metabolic support — where chromium's contribution to normal macronutrient metabolism and normal energy-yielding metabolism aligns with their needs
Chromium supplementation is not appropriate as a substitute for medical treatment. PARTICULAR is a food supplement service, not a medical service. If you have a diagnosed metabolic condition, work with your healthcare professional.
How does PARTICULAR use chromium?
PARTICULAR includes chromium picolinate (code PAR04) at a dose of 20–40 µg, personalised through the questionnaire. This dose sits within the range supported by the EU-authorised claims and reflects the adequate intake level rather than the pharmacological doses used in some clinical trials.
The questionnaire captures information about your diet, health goals and lifestyle factors. When the algorithm identifies metabolic support as relevant to your profile, chromium picolinate is included in your personalised formula.
As with all ingredients in a PARTICULAR formula, chromium is delivered as individually coated microgranules. Each granule has an enteric coating that survives stomach acid, releasing the chromium in the small intestine where absorption occurs. Because each nutrient is in a separate granule, there is no competitive inhibition between minerals at the absorption site.
Your exact formula — including whether chromium is included and at what dose — is calculated individually. No two formulas need to be the same.
Key takeaways
- Chromium is an essential trace mineral that contributes to the maintenance of normal blood glucose levels, normal macronutrient metabolism and normal energy-yielding metabolism — these are EU-authorised health claims under Regulation 432/2012
- Chromium picolinate is the most studied supplemental form, with demonstrated superior absorption compared to chromium chloride and nicotinate forms
- Clinical evidence supports chromium's role in glucose metabolism, particularly in individuals with type 2 diabetes, but it is not a treatment for diabetes
- The evidence for chromium as a weight loss supplement is weak — the authorised claim relates to normal macronutrient metabolism, not weight reduction
- Suboptimal chromium intake is more common than clinical deficiency, particularly in diets high in refined carbohydrates
- PARTICULAR uses chromium picolinate at 20–40 µg, personalised via the questionnaire and delivered as enteric-coated microgranules for optimal absorption
Sources cited in this article:
- Havel PJ. "A scientific review: the role of chromium in insulin resistance." Diabetes Educ. 2004;Suppl:2-14.
- DiSilvestro RA, Dy E. "Comparison of acute absorption of commercially available chromium supplements." J Trace Elem Med Biol. 2007;21(2):120-4.
- Laschinsky N, Kottwitz K, Freund B, et al. "Bioavailability of chromium(III)-supplements in rats and humans." Biometals. 2012;25(5):1051-60.
- Anderson RA, Cheng N, Bryden NA, et al. "Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes." Diabetes. 1997;46(11):1786-91.
- Balk EM, Tatsioni A, Lichtenstein AH, et al. "Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials." Diabetes Care. 2007;30(8):2154-63.
- Pittler MH, Stevinson C, Ernst E. "Chromium picolinate for reducing body weight: meta-analysis of randomized trials." Int J Obes Relat Metab Disord. 2003;27(4):522-9.
- EU Commission Regulation 432/2012 — Authorised health claims made on foods.